Targeting of mutant NY-PR-1 in breast cancer using chimeric antigen receptor engineered T
|Subject:||CELLULAR BIOLOGY SHOULD BE DONE BY Alex|
|Order Topic:||Targeting of mutant NY-PR-1 in breast cancer using chimeric antigen receptor engineered T cells|
Targeting of mutant NY-PR-1 in breast cancer using chimeric antigen
receptor engineered T cells
Control animals will be injected IP route with a similar volume of PBS. This step is required to test
the toxicity of the therapeutic approach.
Quality Control Step
– All animal experiments will be conducted in accordance with accepted standards of animal care and
agreement with a protocol established with Ethics committee.
– Tumor growth will be monitored by Bioluminescence imaging.
– Dosing sites, injection volume and needle size should be carefully considered to minimize the
– Function of Indium – labeled T cells is confirmed by their ability to produce serum concentration of
cytokines ( INF-γ , IL-6 and TNF-α ) using ELISA and by their ability to elicit destruction of
tumor using SPECT-CT imaging